This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

9

Spl Product Data Elements

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM LOSARTAN HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE SILICON DIOXIDE CELLULOSE, MICROCRYSTALLINE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED STARCH, CORN POLYETHYLENE GLYCOL, UNSPECIFIED WHITE TO OFF WHITE CAPSULE ZD18 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE LOSARTAN POTASSIUM LOSARTAN HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE SILICON DIOXIDE CELLULOSE, MICROCRYSTALLINE HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED STARCH, CORN POLYETHYLENE GLYCOL, UNSPECIFIED WHITE TO OFF-WHITE CAPSULE ZD19

Application Number

ANDA078385

Brand Name

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Generic Name

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Product Ndc

65841-733

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-732-06 Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg 30 Tablets Rx Only NDC 65841-733-06 Losartan Potassium and Hydrochlorothiazide Tablets USP, 100 mg/25 mg 30 Tablets Rx Only losahctz3 losahctz4

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.